Copyright Reports & Markets. All rights reserved.

Global Endocannabinoid System Targeted Therapeutics Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Market Analysis by Route of Administration
    • 1.3.1 Global Endocannabinoid System Targeted Therapeutics Market Size Growth Rate by Route of Administration: 2020 VS 2026
    • 1.3.2 Oral
    • 1.3.3 Inhalation
    • 1.3.4 Others
  • 1.4 Market by Application
    • 1.4.1 Global Endocannabinoid System Targeted Therapeutics Market Share by Application: 2020 VS 2026
    • 1.4.2 Autoimmune Disorders
    • 1.4.3 Genetic Disorders
    • 1.4.4 Neurological Disorders
    • 1.4.5 Pain Disorders
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Endocannabinoid System Targeted Therapeutics Market Perspective (2015-2026)
  • 2.2 Endocannabinoid System Targeted Therapeutics Growth Trends by Regions
    • 2.2.1 Endocannabinoid System Targeted Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Endocannabinoid System Targeted Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Endocannabinoid System Targeted Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Endocannabinoid System Targeted Therapeutics Industry Dynamic
    • 2.3.1 Endocannabinoid System Targeted Therapeutics Market Trends
    • 2.3.2 Endocannabinoid System Targeted Therapeutics Market Drivers
    • 2.3.3 Endocannabinoid System Targeted Therapeutics Market Challenges
    • 2.3.4 Endocannabinoid System Targeted Therapeutics Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Endocannabinoid System Targeted Therapeutics Players by Market Size
    • 3.1.1 Global Top Endocannabinoid System Targeted Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Endocannabinoid System Targeted Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.2 Global Endocannabinoid System Targeted Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Endocannabinoid System Targeted Therapeutics Revenue
  • 3.4 Global Endocannabinoid System Targeted Therapeutics Market Concentration Ratio
    • 3.4.1 Global Endocannabinoid System Targeted Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Endocannabinoid System Targeted Therapeutics Revenue in 2019
  • 3.5 Key Players Endocannabinoid System Targeted Therapeutics Area Served
  • 3.6 Key Players Endocannabinoid System Targeted Therapeutics Product Solution and Service
  • 3.7 Date of Enter into Endocannabinoid System Targeted Therapeutics Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Endocannabinoid System Targeted Therapeutics Breakdown Data by Route of Administration

  • 4.1 Global Endocannabinoid System Targeted Therapeutics Historic Market Size by Route of Administration (2015-2020)
  • 4.2 Global Endocannabinoid System Targeted Therapeutics Forecasted Market Size by Route of Administration (2021-2026)

5 Endocannabinoid System Targeted Therapeutics Breakdown Data by Application

  • 5.1 Global Endocannabinoid System Targeted Therapeutics Historic Market Size by Application (2015-2020)
  • 5.2 Global Endocannabinoid System Targeted Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Endocannabinoid System Targeted Therapeutics Market Size (2015-2026)
  • 6.2 North America Endocannabinoid System Targeted Therapeutics Market Size by Route of Administration (2015-2020)
  • 6.3 North America Endocannabinoid System Targeted Therapeutics Market Size by Application (2015-2020)
  • 6.4 North America Endocannabinoid System Targeted Therapeutics Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Endocannabinoid System Targeted Therapeutics Market Size (2015-2026)
  • 7.2 Europe Endocannabinoid System Targeted Therapeutics Market Size by Route of Administration (2015-2020)
  • 7.3 Europe Endocannabinoid System Targeted Therapeutics Market Size by Application (2015-2020)
  • 7.4 Europe Endocannabinoid System Targeted Therapeutics Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Endocannabinoid System Targeted Therapeutics Market Size (2015-2026)
  • 8.2 Asia-Pacific Endocannabinoid System Targeted Therapeutics Market Size by Route of Administration (2015-2020)
  • 8.3 Asia-Pacific Endocannabinoid System Targeted Therapeutics Market Size by Application (2015-2020)
  • 8.4 Asia-Pacific Endocannabinoid System Targeted Therapeutics Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia

9 Latin America

  • 9.1 Latin America Endocannabinoid System Targeted Therapeutics Market Size (2015-2026)
  • 9.2 Latin America Endocannabinoid System Targeted Therapeutics Market Size by Route of Administration (2015-2020)
  • 9.3 Latin America Endocannabinoid System Targeted Therapeutics Market Size by Application (2015-2020)
  • 9.4 Latin America Endocannabinoid System Targeted Therapeutics Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Endocannabinoid System Targeted Therapeutics Market Size (2015-2026)
  • 10.2 Middle East & Africa Endocannabinoid System Targeted Therapeutics Market Size by Type (2015-2020)
  • 10.3 Middle East & Africa Endocannabinoid System Targeted Therapeutics Market Size by Application (2015-2020)
  • 10.4 Middle East & Africa Endocannabinoid System Targeted Therapeutics Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE

11Key Players Profiles

  • 11.1 GW Pharmaceuticals
    • 11.1.1 GW Pharmaceuticals Company Details
    • 11.1.2 GW Pharmaceuticals Business Overview
    • 11.1.3 GW Pharmaceuticals Endocannabinoid System Targeted Therapeutics Introduction
    • 11.1.4 GW Pharmaceuticals Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020))
    • 11.1.5 GW Pharmaceuticals Recent Development
  • 11.2 MAKScientific
    • 11.2.1 MAKScientific Company Details
    • 11.2.2 MAKScientific Business Overview
    • 11.2.3 MAKScientific Endocannabinoid System Targeted Therapeutics Introduction
    • 11.2.4 MAKScientific Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.2.5 MAKScientific Recent Development
  • 11.3 Corbus Pharmaceuticals
    • 11.3.1 Corbus Pharmaceuticals Company Details
    • 11.3.2 Corbus Pharmaceuticals Business Overview
    • 11.3.3 Corbus Pharmaceuticals Endocannabinoid System Targeted Therapeutics Introduction
    • 11.3.4 Corbus Pharmaceuticals Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.3.5 Corbus Pharmaceuticals Recent Development
  • 11.4 Tilray
    • 11.4.1 Tilray Company Details
    • 11.4.2 Tilray Business Overview
    • 11.4.3 Tilray Endocannabinoid System Targeted Therapeutics Introduction
    • 11.4.4 Tilray Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.4.5 Tilray Recent Development
  • 11.5 Pure Green
    • 11.5.1 Pure Green Company Details
    • 11.5.2 Pure Green Business Overview
    • 11.5.3 Pure Green Endocannabinoid System Targeted Therapeutics Introduction
    • 11.5.4 Pure Green Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.5.5 Pure Green Recent Development
  • 11.6 Avicanna
    • 11.6.1 Avicanna Company Details
    • 11.6.2 Avicanna Business Overview
    • 11.6.3 Avicanna Endocannabinoid System Targeted Therapeutics Introduction
    • 11.6.4 Avicanna Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.6.5 Avicanna Recent Development
  • 11.7 GB Sciences
    • 11.7.1 GB Sciences Company Details
    • 11.7.2 GB Sciences Business Overview
    • 11.7.3 GB Sciences Endocannabinoid System Targeted Therapeutics Introduction
    • 11.7.4 GB Sciences Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.7.5 GB Sciences Recent Development
  • 11.8 Botanix Pharmaceuticals
    • 11.8.1 Botanix Pharmaceuticals Company Details
    • 11.8.2 Botanix Pharmaceuticals Business Overview
    • 11.8.3 Botanix Pharmaceuticals Endocannabinoid System Targeted Therapeutics Introduction
    • 11.8.4 Botanix Pharmaceuticals Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.8.5 Botanix Pharmaceuticals Recent Development
  • 11.9 Therapix Biosciences
    • 11.9.1 Therapix Biosciences Company Details
    • 11.9.2 Therapix Biosciences Business Overview
    • 11.9.3 Therapix Biosciences Endocannabinoid System Targeted Therapeutics Introduction
    • 11.9.4 Therapix Biosciences Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.9.5 Therapix Biosciences Recent Development
  • 11.10 Zelira Therapeutics
    • 11.10.1 Zelira Therapeutics Company Details
    • 11.10.2 Zelira Therapeutics Business Overview
    • 11.10.3 Zelira Therapeutics Endocannabinoid System Targeted Therapeutics Introduction
    • 11.10.4 Zelira Therapeutics Revenue in Endocannabinoid System Targeted Therapeutics Business (2015-2020)
    • 11.10.5 Zelira Therapeutics Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Endocannabinoid System Targeted Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Endocannabinoid System Targeted Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Route of Administration and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Route of Administration, the product can be split into
    Oral
    Inhalation
    Others

    Market segment by Application, split into
    Autoimmune Disorders
    Genetic Disorders
    Neurological Disorders
    Pain Disorders

    Based on regional and country-level analysis, the Endocannabinoid System Targeted Therapeutics market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    In the competitive analysis section of the report, leading as well as prominent players of the global Endocannabinoid System Targeted Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    GW Pharmaceuticals
    MAKScientific
    Corbus Pharmaceuticals
    Tilray
    Pure Green
    Avicanna
    GB Sciences
    Botanix Pharmaceuticals
    Therapix Biosciences

    Buy now